[{"address1": "12790 El Camino Real", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "760 593 4832", "website": "https://ventyxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.", "fullTimeEmployees": 81, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sheila K. Gujrathi M.D.", "age": 54, "title": "Executive Chairperson", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 125000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raju S. Mohan Ph.D.", "age": 66, "title": "Founder, CEO, President & Director", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 979215, "exercisedValue": 0, "unexercisedValue": 5922}, {"maxAge": 1, "name": "Mr. Matthew Richard Moore", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 612510, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark S. Forman M.D., Ph.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 380965, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Roy M. Gonzales CPA, M.B.A.", "age": 48, "title": "Senior VP of Finance and Principal Financial & Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John M. Nuss Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 630635, "exercisedValue": 0, "unexercisedValue": 451580}, {"maxAge": 1, "name": "Ms. Snehal  Naik Ph.D.", "title": "Senior VP of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathy  Ogilvie Ph.D.", "title": "Senior VP of Translational & Nonclinical Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rosa  Ferrao", "title": "Senior VP of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.21, "open": 1.2, "dayLow": 1.2, "dayHigh": 1.41, "regularMarketPreviousClose": 1.21, "regularMarketOpen": 1.2, "regularMarketDayLow": 1.2, "regularMarketDayHigh": 1.41, "payoutRatio": 0.0, "beta": 0.727, "forwardPE": -0.65116274, "volume": 1893187, "regularMarketVolume": 1893187, "averageVolume": 1003120, "averageVolume10days": 981200, "averageDailyVolume10Day": 981200, "bid": 1.35, "ask": 1.43, "bidSize": 1, "askSize": 3, "marketCap": 99625680, "fiftyTwoWeekLow": 0.783, "fiftyTwoWeekHigh": 5.66, "fiftyDayAverage": 1.22116, "twoHundredDayAverage": 1.900165, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -118634320, "profitMargins": 0.0, "floatShares": 54963488, "sharesOutstanding": 71161200, "sharesShort": 7220534, "sharesShortPriorMonth": 7350657, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.1015, "heldPercentInsiders": 0.04133, "heldPercentInstitutions": 0.67854, "shortRatio": 5.57, "shortPercentOfFloat": 0.1078, "impliedSharesOutstanding": 81159104, "bookValue": 3.255, "priceToBook": 0.4301075, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -123990000, "trailingEps": -1.74, "forwardEps": -2.15, "enterpriseToEbitda": 0.869, "52WeekChange": -0.7494824, "SandP52WeekChange": 0.11469197, "quoteType": "EQUITY", "currentPrice": 1.4, "targetHighPrice": 21.0, "targetLowPrice": 2.0, "targetMeanPrice": 12.0, "targetMedianPrice": 12.5, "recommendationMean": 1.77778, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 228807008, "totalCashPerShare": 3.215, "ebitda": -136483008, "totalDebt": 10547000, "quickRatio": 18.501, "currentRatio": 19.571, "debtToEquity": 4.553, "returnOnAssets": -0.29198, "returnOnEquity": -0.46039, "freeCashflow": -61715876, "operatingCashflow": -108966000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VTYX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1634823000000, "shortName": "Ventyx Biosciences, Inc.", "corporateActions": [], "postMarketTime": 1747439634, "regularMarketTime": 1747425600, "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "earningsTimestamp": 1746734460, "earningsTimestampStart": 1746734460, "earningsTimestampEnd": 1746734460, "earningsCallTimestampStart": 1715286600, "earningsCallTimestampEnd": 1715286600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.74, "epsForward": -2.15, "epsCurrentYear": -1.93, "priceEpsCurrentYear": -0.7253886, "fiftyDayAverageChange": 0.17883992, "fiftyDayAverageChangePercent": 0.14645085, "twoHundredDayAverageChange": -0.500165, "twoHundredDayAverageChangePercent": -0.2632219, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-21", "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "longName": "Ventyx Biosciences, Inc.", "regularMarketChangePercent": 15.702475, "regularMarketPrice": 1.4, "marketState": "CLOSED", "postMarketChangePercent": -5.71428, "postMarketPrice": 1.32, "postMarketChange": -0.0799999, "regularMarketChange": 0.18999994, "regularMarketDayRange": "1.2 - 1.41", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1003120, "fiftyTwoWeekLowChange": 0.617, "fiftyTwoWeekLowChangePercent": 0.78799486, "fiftyTwoWeekRange": "0.783 - 5.66", "fiftyTwoWeekHighChange": -4.2599998, "fiftyTwoWeekHighChangePercent": -0.75265014, "fiftyTwoWeekChangePercent": -74.94824, "exchange": "NMS", "messageBoardId": "finmb_672535556", "exchangeTimezoneName": "America/New_York", "displayName": "Ventyx Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-05-17"}]